Discovery

Rutgers University

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

DuPont Nutrition & Biosciences Announces Research Collaboration with Rutgers University

Lead Product(s): Gut-Microbiome

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Dupont Nutrition & Health

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 23, 2020

Details:

The two-year research partnership will focus on improving the benefit/risk ratio of chemotherapy by decreasing gut inflammation caused by chemotherapy to potentially improve response rates through modulation of the microbiome.

Jnana Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Jnana Therapeutics Enters Collaboration with Roche to Discover Novel Medicines that Target Key Regulators of Cellular Metabolism

Lead Product(s): Undisclosed

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

Deal Size: $1,040.0 million Upfront Cash: $40.0 million

Deal Type: Collaboration July 21, 2020

Details:

Under the terms of the agreement, Jnana will partner with Roche on discovery and preclinical development for a broad set of targets across immunology and neuroscience, which Roche will further develop and commercialize exclusively.

Can-Fite BioPharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds

Lead Product(s): Cannabis derived compounds

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 20, 2020

Details:

Can-Fite has completed the development of a biological cell-based in vitro assay which can identify clinically active cannabis derived compounds that bind to and activate the A3 adenosine receptor (A3AR).

Dragonfly Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Dragonfly Therapeutics Announces Collaboration with BMS to Develop Novel Therapeutic Candidates for M.S and Neuro-inflammation Targets

Lead Product(s): NK cell Engager Therapies

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Bristol-Myers Squibb

Deal Size: Undisclosed Upfront Cash: $55.0 million

Deal Type: Licensing Agreement July 06, 2020

Details:

Under the agreement, Dragonfly will grant Bristol Myers Squibb the option to license exclusive worldwide intellectual property rights to multiple candidates developed using Dragonfly's proprietary platform for multiple new targets.

HitGen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

HitGen and Morphic Extend Drug Discovery Research Collaboration

Lead Product(s): Undisclosed

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Morphic Therapeutic

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 06, 2020

Details:

Under the terms of the extended agreement, HitGen will use its platform technology, based on the design, synthesis and interrogation by selection of DELs to discover ligands for targets of interest to Morphic.

Hemogenyx Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Hemogenyx Pharmaceuticals PLC Announces Development Agreement - Autoimmune Disease Treatments

Lead Product(s): Undisclosed

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Hemogenyx Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 26, 2020

Details:

GlobalCo will supply the Company with certain biological materials and related confidential information in order for the Company to perform research and development activities to discover and validate novel materials for the treatment of SLE and ther autoimmune diseases.

SIGA Technologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

SIGA Announces Deliveries of Oral TPOXX® to HHS Valued at Approximately $32 Million

Lead Product(s): Tecovirimat

Therapeutic Area: Immunology Product Name: Tpoxx

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: BARDA

Deal Size: $414.0 million Upfront Cash: Undisclosed

Deal Type: Agreement June 25, 2020

Details:

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the deliveries of oral TPOXX® (tecovirimat) to the U.S. Department of Health and Human Services (HHS).

SIGA Technologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

SIGA Technologies Announces Department of Defense Increases Funding to Develop Post-Exposure Prophylactic Indication for TPOXX®

Lead Product(s): Tecovirimat

Therapeutic Area: Immunology Product Name: Tpoxx

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: JPEO-CBRND

Deal Size: $23.0 million Upfront Cash: Undisclosed

Deal Type: Funding June 15, 2020

Details:

Funding will support work necessary to gain a potential label expansion from the U.S. FDA for TPOXX® (tecovirimat) for Post-Exposure Prophylaxis (PEP) in addition to the current approved labeling for the treatment of smallpox.

HotSpot Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

SR One fuels HotSpot's $65M B round to fund allosteric R&D

Lead Product(s): Undisclosed

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: S.R. One

Deal Size: $65.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing May 21, 2020

Details:

The Series B financing will support the advancement of HotSpot’s lead programs to the clinic, including protein kinase C (PKC-theta) antagonists for Th2 and T-reg driven autoimmune disease and S6 kinase (S6K) antagonists for rare metabolic disease.

Dyno Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Dyno Therapeutics Announces Presentations at 2020 American Society of Gene and Cell Therapy Conference

Lead Product(s): Synthetic AAV capsids Proteins

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 12, 2020

Details:

The presentation will highlight results from Dyno's study on Artificial intelligence powered design of synthetic AAV capsids without pre-existing immunity for the universal treatment of all patients.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Rutgers University

DuPont Nutrition & Biosciences Announces Research Collaboration with Rutgers University

Jnana Therapeutics

Jnana Therapeutics Enters Collaboration with Roche to Discover Novel Medicines that Target Key Regulators of Cellular Metabolism

Can-Fite BioPharma

Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds

Dragonfly Therapeutics

Dragonfly Therapeutics Announces Collaboration with BMS to Develop Novel Therapeutic Candidates for M.S and Neuro-inflammation Targets

HitGen

HitGen and Morphic Extend Drug Discovery Research Collaboration

Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals PLC Announces Development Agreement - Autoimmune Disease Treatments

SIGA Technologies

SIGA Announces Deliveries of Oral TPOXX® to HHS Valued at Approximately $32 Million

SIGA Technologies

SIGA Technologies Announces Department of Defense Increases Funding to Develop Post-Exposure Prophylactic Indication for TPOXX®

HotSpot Therapeutics

SR One fuels HotSpot's $65M B round to fund allosteric R&D

Dyno Therapeutics

Dyno Therapeutics Announces Presentations at 2020 American Society of Gene and Cell Therapy Conference